DDInter732 DDInter899
Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamines, such as [diphenhydramine], which readily bind to off-targets that contribute to side effects such as sedation. Fexofenadine is the major active metabolite of [terfenadine] and is administered as a racemic mixture in which both enantiomers display approximately equivalent antihistamine activity.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Fexofenadine {u} (Compound) resembles {v} (Compound) Pimozide
Fexofenadine {u} (Compound) resembles {v} (Compound) Diphenoxylate
Fexofenadine {u} (Compound) binds {v} (Gene) SLCO1A2
Fexofenadine {u} (Compound) upregulates {v} (Gene) UBQLN2
Fexofenadine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine H1 Receptor Antagonists
Fexofenadine {u} (Compound) downregulates {v} (Gene) GDF15
Fexofenadine {u} (Compound) causes {v} (Side Effect) Agitation
Fexofenadine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Voriconazole
Fexofenadine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Troleandomycin
Fexofenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Fexofenadine (Compound) resembles Pimozide (Compound)
Fexofenadine (Compound) resembles Diphenoxylate (Compound)
Fexofenadine (Compound) binds SLCO1A2 (Gene)
Fexofenadine (Compound) upregulates UBQLN2 (Gene)
Fexofenadine (Compound) is included by Histamine H1 Receptor Antagonists (Pharmacologic Class)
Fexofenadine (Compound) downregulates GDF15 (Gene)
Fexofenadine (Compound) causes Agitation (Side Effect)
Fexofenadine may cause a minor interaction that can limit clinical effects when taken with Voriconazole
Fexofenadine may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib